Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury
1 other identifier
observational
300
1 country
1
Brief Summary
The aim is to describe the epidemiology and determine the independent risk factors for mortality and acute organ injury in AKI and to assess the impact of different treatment strategies on survival. This will allow the development of prevention strategies and design of appropriately powered intervention studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 27, 2020
CompletedStudy Start
First participant enrolled
June 20, 2020
CompletedFirst Posted
Study publicly available on registry
June 24, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedAugust 4, 2021
August 1, 2021
2.1 years
May 27, 2020
August 3, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of any stage of acute kidney injury
As defined by Kidney Diseases: Improving Global Outcomes (KDIGO) criteria
14 days
Secondary Outcomes (8)
Mortality
14-day, hospital, and intensive care unit (ICU) mortality
Renal recovery
14 days
Percentage of patients who receive renal replacement therapy
14 days
Percentage of participants who are dialysis dependent
Through study completion, an average of 90 days
Free-days of vasoactive medications and mechanical ventilation
Day 30
- +3 more secondary outcomes
Study Arms (1)
Critically Ill Patients with COVID-19
We plan to recruit patients who are admitted to intensive care units with COVID-19 diagnosis.
Eligibility Criteria
Adult critically ill patients with confirmed diagnosis of COVID-19
You may qualify if:
- Adults (aged ≥18 years)
- Confirmed diagnosis of COVID-19
- Hospitalized in the ICU for illness related to COVID-19
- Any of the following:
- Current in-patient in ICU
- Previous in-patient in ICU and died in ICU or hospital
- Previous in-patient in ICU and discharged from ICU alive
You may not qualify if:
- Younger than 18 years old
- On chronic dialysis within the last year or on dialysis at ICU admission
- Functioning kidney transplant
- No creatinine within 48 hours of ICU admission
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guy's & St Thomas' Hospital
London, SE1 7EH, United Kingdom
Related Publications (2)
Lumlertgul N, Baker E, Pearson E, Dalrymple KV, Pan J, Jheeta A, Weerapolchai K, Wang Y, Leach R, Barrett NA, Ostermann M. Changing epidemiology of acute kidney injury in critically ill patients with COVID-19: a prospective cohort. Ann Intensive Care. 2022 Dec 28;12(1):118. doi: 10.1186/s13613-022-01094-6.
PMID: 36575315DERIVEDLumlertgul N, Pirondini L, Cooney E, Kok W, Gregson J, Camporota L, Lane K, Leach R, Ostermann M. Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study. Ann Intensive Care. 2021 Aug 6;11(1):123. doi: 10.1186/s13613-021-00914-5.
PMID: 34357478DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nuttha Lumlertgul, MD, PhD
Guy's & St Thomas' Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 27, 2020
First Posted
June 24, 2020
Study Start
June 20, 2020
Primary Completion
July 31, 2022
Study Completion
December 31, 2022
Last Updated
August 4, 2021
Record last verified: 2021-08